[HTML][HTML] Covid-19—navigating the uncharted

AS Fauci, HC Lane, RR Redfield - 2020 - Mass Medical Soc
Covid-19—Navigating the Uncharted Fauci, Lane, and Redfield comment on the early
clinical features and epidemiology of cases reported in Wuhan, China, along with current
mortality data, noting that the outbreak is a stark reminder of the need for constant …

[HTML][HTML] The COVID19 epidemic

TP Velavan, CG Meyer - Tropical medicine & international health, 2020 - ncbi.nlm.nih.gov
The current outbreak of the novel coronavirus SARS-CoV-2 (coronavirus disease 2019;
previously 2019-nCoV), epi-centred in Hubei Province of the People's Republic of China,
has spread to many other countries. On 30. January 2020, the WHO Emergency Committee …

[PDF][PDF] The COVID-19 vaccine development landscape

TT Le, Z Andreadakis, A Kumar, RG Román… - Nat Rev Drug …, 2020 - researchgate.net
Profile of vaccine developers. Of the confirmed active vaccine candidates, 56 (72%) are
being developed by private/industry developers, with the remaining 22 (28%) of projects
being led by academic, public sector and other non-profit organizations (Fig. 2). Although a …

[HTML][HTML] COVID-19: immunopathology and its implications for therapy

X Cao - Nature reviews immunology, 2020 - nature.com
Severe coronavirus disease 2019 (COVID-19) is characterized by pneumonia, lymphopenia,
exhausted lymphocytes and a cytokine storm. Significant antibody production is observed;
however, whether this is protective or pathogenic remains to be determined. Defining the …

Anosmia and ageusia: common findings in COVID19 patients

LA Vaira, G Salzano, G Deiana, G De Riu - The Laryngoscope, 2020 - Wiley Online Library
RAPID COMMUNICATION Europe and America currently represent the new front where the battle
against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is being fought. In the
management of the health crisis, the identification of paucisymptomatic patients is emerging …

[HTML][HTML] COVID-19: immunopathogenesis and Immunotherapeutics

L Yang, S Liu, J Liu, Z Zhang, X Wan… - Signal transduction and …, 2020 - nature.com
The recent novel coronavirus disease (COVID-19) outbreak, caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), is seeing a rapid increase in infected
patients worldwide. The host immune response to SARS-CoV-2 appears to play a critical …

[HTML][HTML] Remdesivir for the treatment of Covid-19

JH Beigel, KM Tomashek, LE Dodd… - … England Journal of …, 2020 - Mass Medical Soc
Background Although several therapeutic agents have been evaluated for the treatment of
coronavirus disease 2019 (Covid-19), no antiviral agents have yet been shown to be
efficacious. Methods We conducted a double-blind, randomized, placebo-controlled trial of …

COVID-19 pathophysiology: A review

K Yuki, M Fujiogi, S Koutsogiannaki - Clinical immunology, 2020 - Elsevier
In December 2019, a novel coronavirus, now named as SARS-CoV-2, caused a series of
acute atypical respiratory diseases in Wuhan, Hubei Province, China. The disease caused
by this virus was termed COVID-19. The virus is transmittable between humans and has …

The rheumatologist's role in COVID-19

RQ Cron, WW Chatham - 2020 - jrheum.org
The novel coronavirus (severe acute respiratory syndrome; SARS-CoV-2) pandemic has
spread rapidly throughout the planet. It is believed to have originated in the Wuhan province
of China, but this highly contagious respiratory virus has spread to over 140 countries on 6 …

[HTML][HTML] Post-COVID-19 global health strategies: the need for an interdisciplinary approach

GA COVID… - Aging Clinical and …, 2020 - ncbi.nlm.nih.gov
For survivors of severe COVID-19 disease, having defeated the virus is just the beginning of
an uncharted recovery path. What follows after the acute phase of SARS-CoV-2 infection
depends on the extension and severity of viral attacks in different cell types and organs …